TMCnet News
Foundation Medicine and Collaborators to Present New Data in 12 Oral and Poster Presentations at the AACR Annual MeetingFoundation Medicine, Inc. (NASDAQ:FMI) today announced that the company and its collaborators will present 12 oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2015 taking place April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia. "We are extremely encouraged by the breadth of clinical data enabled by Foundation Medicine's platform being presented at this year's AACR annual meeting," said Vincent Miller, M.D., chief medical officer, Foundation Medicine. "These data elucidate the benefits and value of integrating clinically relevant and highly reliable molecular information into oncologic clinical practice. Cancer is a complex disease to treat and manage, and Foundation Medicine's singular comprehensive genomic profiling approach arms physicians with the right information to enable informed, outcomes-oriented treatment decisions for patients." The company's molecular information products, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the genomic alterations in a patient's cancer. The data to be presented at AACR add to a growing body of evidence revealing the critical distinctions between hotspot-based testing, which analyses a single or small set of genes or a specific region in such genes, and validated comprehensive genomic profiles, which analyze the entire coding regions of cancer genes and detect all four classes of genomic alterations. The schedule for oral presentations by Foundation Medicine and/or its collaborators is as follows:
Date & Time: Sunday, April 19, 2015 from 3:20 to 3:35 p.m. ET
Date & Time: Tuesday, April 21, 2015 from 3:20 to 3:35 p.m. ET The schedule for poster presentations by Foundation Medicine and/or its collaborators is as follows:
Date & Time: Sunday, April 19, 2015 from 1:00 to 5:00 p.m. ET
Date & Time: Sunday, April 19, 2015 from 1:00 to 5:00 p.m. ET
Date & Time: Monday, April 20, 2015 from 8:00 a.m. to 12:00
p.m. ET
Date & Time: Monday, April 20, 2015 from 8:00 a.m. to 12:00
p.m. ET
Date & Time: Tuesday, April 21, 2015 from 8:00 a.m. to 12:00
p.m. ET
Date & Time: Tuesday, April 21, 2015 from 1:00 to 5:00 p.m. ET
Date & Time: Wednesday, April 22, 2015 from 8:00 a.m. to
12:00 p.m. ET
Date & Time: Wednesday, April 22, 2015 from 8:00 a.m. to
12:00 p.m. ET About Foundation Medicine Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (News - Alert) (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of molecular information and Foundation Medicine's comprehensive genomic profiling to improve treatment decisions for patients. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that Foundation Medicine's comprehensive genomic profiling will not be able to identify genomic alterations in the same manner as prior clinical data, and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission, may be realized. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.
|